Literature DB >> 1350058

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.

M R Luquin1, O Scipioni, J Vaamonde, O Gershanik, J A Obeso.   

Abstract

Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) may be classified into three main categories: "On" dyskinesias, diphasic dyskinesias (DD), and "off" periods. The study of 168 parkinsonian patients showed that about half (n = 84) showed one pattern of LID only. A combination of two was present in 68, and 16 had the three presentation patterns. A fairly good correlation between type of dyskinesia and presentation pattern was established. Chorea, myoclonus, and dystonic movements occurred during the "on" period. Dystonic postures, particularly affecting the feet, were mainly present in the "off" period, but a few patients had a diphasic presentation. Repetitive stereotyped movements of the lower limbs always corresponded to DD. Acute pharmacological tests using dopamine agonists (subcutaneous apomorphine 3-8 mg; intravenous lisuride 0.1-0.15 mg) and dopamine antagonists (intravenous sulpiride 200-400 mg and intravenous chlorpromazine 25 mg) were performed in 40 patients. Dopamine agonists enhanced "on" dyskinesias and markedly reduced or abolished "off" period dystonia and DD. Dopamine antagonists reduced all types of LID but usually aggravated parkinsonism. These clinical and pharmacological results indicate that LID in PD are a heterogeneous phenomenon difficult to explain on the basis of a single pathophysiological mechanism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350058     DOI: 10.1002/mds.870070204

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  36 in total

Review 1.  Bromocriptine for levodopa-induced motor complications in Parkinson's disease.

Authors:  J J van Hilten; C Ramaker; W J Van de Beek; M J Finken
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

Authors:  Yunmin Ding; Jacqueline Restrepo; Lisa Won; Dong-Youn Hwang; Kwang-Soo Kim; Un Jung Kang
Journal:  Neurobiol Dis       Date:  2007-04-10       Impact factor: 5.996

4.  Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.

Authors:  J L Tillerson; A D Cohen; J Philhower; G W Miller; M J Zigmond; T Schallert
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

Review 5.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 6.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

7.  Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.

Authors:  Vincent A Jourdain; Chris C Tang; Florian Holtbernd; Christian Dresel; Yoon Young Choi; Yilong Ma; Vijay Dhawan; David Eidelberg
Journal:  JCI Insight       Date:  2016-09-22

Review 8.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

Review 9.  Methods of managing levodopa-induced dyskinesias.

Authors:  L T Giron; W C Koller
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

Review 10.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.